Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
2024
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously.
Using Polygenic Risk Scores to Stratify Patients Based on Risk of Invasive Cutaneous Melanoma
Polygenic risk scores (PRS) may serve as a viable tool to stratify patients based on their risk of invasive melanoma, according to a study published in JAMA Dermatology.
A newly approved ‘living drug’ could save more cancer patients’ lives
Toni English’s medical team was giddy.